Sepsis Endotypes for Precision Therapy: Towards Individualized Management in Critical Care

Abstract

Sepsis remains a significant cause of morbidity and mortality worldwide, characterized by a heterogeneous host response to infection. Recent advances in molecular profiling have identified distinct sepsis endotypes, paving the way for precision therapy. This review synthesizes the latest evidence on sepsis endotyping, discusses underlying mechanisms, evaluates clinical implications, and provides a comprehensive overview of diagnostic and therapeutic strategies tailored to endotype-specific responses. Emphasis is placed on integrating emerging molecular insights into clinical practice for improved patient outcomes.

Introduction

Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection. Despite decades of research, sepsis management remains largely supportive, with high mortality rates and a lack of targeted therapies. Increasing recognition of sepsis as a syndrome with diverse biological underpinnings has driven research into molecular endotyping. Understanding sepsis endotypes distinct host response patterns based on genomics, transcriptomics, proteomics, and clinical features offers the potential for individualized, mechanism-based treatment. This article reviews the epidemiology, pathophysiological basis, risk factors, clinical features, and evolving diagnostic and therapeutic approaches for sepsis endotypes.

Epidemiology / Disease Burden

Globally, sepsis affects an estimated 49 million people annually and accounts for approximately 11 million deaths, representing about 20% of all global deaths. The burden is highest in low- and middle-income countries, but significant morbidity and mortality persist in high-resource settings. The heterogeneity of sepsis presentation contributes to diagnostic challenges and variable outcomes. Recent epidemiological studies suggest that molecular endotyping can stratify patients by risk, response to therapy, and prognosis, highlighting the need for precision medicine approaches in sepsis care.

Pathophysiology

Sepsis pathophysiology involves complex interactions between the infecting pathogen and the host immune response. Traditional paradigms focused on systemic inflammation, but recent research has uncovered a spectrum of immune states, ranging from hyperinflammatory to immunosuppressive profiles. Omics-based studies have identified sepsis endotypes such as the "inflammopathic," "coagulopathic," and "adaptive" subtypes each characterized by distinct gene expression signatures, cytokine profiles, and metabolic pathways. These endotypes are associated with specific clinical trajectories and therapeutic responses, underscoring the importance of mechanism-based stratification in sepsis management.

Risk Factors

Risk factors for sepsis include advanced age, immunosuppression, chronic comorbidities (e.g., diabetes, chronic kidney or liver disease), recent surgery or hospitalization, and invasive medical devices. Genetic susceptibility also plays a role, with certain polymorphisms linked to differential immune responses and endotype predisposition. Identification of endotype-specific risk factors may further refine risk stratification and inform targeted prevention strategies.

Clinical Features

Sepsis presents with a spectrum of clinical features, including fever or hypothermia, tachycardia, tachypnea, hypotension, altered mental status, and evidence of organ dysfunction (e.g., acute kidney injury, coagulopathy, respiratory failure). Endotype classification can aid in recognizing atypical presentations or rapidly deteriorating subgroups. For example, patients with a hyperinflammatory endotype may display severe shock and multi-organ failure, while immunosuppressive endotypes may present with secondary infections and persistent organ dysfunction.

Diagnosis

Diagnosis of sepsis is clinical, supported by laboratory markers of infection and organ dysfunction. Endotyping relies on advanced molecular techniques, including transcriptomics, proteomics, and metabolomics, to identify distinct patient subgroups. Biomarkers such as IL-6, procalcitonin, and gene expression panels (e.g., sepsis response signature, SRS1/SRS2) have shown promise in distinguishing endotypes. Integration of these molecular diagnostics with clinical assessment may enable earlier and more precise identification of sepsis phenotypes, guiding personalized therapy.

Treatment & Management

Current sepsis management focuses on prompt antimicrobial therapy, source control, hemodynamic support, and organ function monitoring. However, a one-size-fits-all approach may be suboptimal given endotype heterogeneity. Precision therapy entails tailoring interventions based on endotype, such as immunomodulatory therapies for hyperinflammatory subtypes or immune-stimulatory agents for immunosuppressed patients. Ongoing trials are evaluating the efficacy of endotype-guided interventions, including corticosteroids, cytokine inhibitors, and immune checkpoint modulators.

Recent Advances / Emerging Therapies

Recent advances in high-throughput sequencing and machine learning have enabled real-time endotype classification. Clinical trials increasingly incorporate endotype stratification to assess differential treatment effects. Notable emerging therapies include targeted cytokine blockade (e.g., anti-IL-6), immune checkpoint inhibition for sepsis-induced immunosuppression, and precision antibiotic strategies guided by host response profiles. The integration of electronic health records with molecular data is also facilitating the development of decision-support tools for endotype-driven sepsis care.

Guideline Recommendations

International guidelines, such as those from the Surviving Sepsis Campaign, emphasize the importance of early recognition, prompt antimicrobial therapy, and supportive care. While molecular endotyping is not yet standard of care, guidelines increasingly advocate for research into stratified approaches and recommend considering patient heterogeneity in clinical decision-making. Future guidelines are expected to incorporate validated endotyping tools as evidence matures.

Conclusion

The identification and clinical application of sepsis endotypes represent a paradigm shift towards precision therapy in critical care. Molecular endotyping holds promise for improving prognosis, personalizing treatment, and reducing sepsis-related mortality. Ongoing research and integration of molecular diagnostics into routine practice will be essential for realizing the full potential of endotype-guided sepsis management.